TSE:4528Pharmaceuticals
Ono Pharmaceutical (TSE:4528) Is Down 7.0% After Gastric Cancer Drug ONO-4578 Advances To Phase 3 – Has The Bull Case Changed?
In early June 2026, Ono Pharmaceutical reported phase 2 data showing its EP4 antagonist ONO-4578, combined with nivolumab and chemotherapy, improved progression-free survival and other efficacy measures versus placebo in previously untreated, HER2-negative unresectable advanced or recurrent gastric cancer, without new safety concerns.
The benefit was especially marked in patients with PD-L1 CPS ≥1, and Ono, together with affiliate Deciphera, now plans a pivotal phase 3 study to test...